HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

  • STATUS
    Recruiting
  • End date
    May 31, 2023
  • participants needed
    1400
  • sponsor
    Columbia University
Updated on 26 May 2022

Summary

This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, as well as measuring the completion of the vaccination series among those living with HIV and those who are not infected with HIV.

Description

Cervical cancer remains a significant threat to public health worldwide and remains the leading cause of cancer-associated mortality in women in Sub Saharan Africa. Cervical cancer-associated morbidity and mortality is preventable through HPV vaccination, and screening and treatment of pre-cancerous lesions. To date, there is no nationwide HPV vaccination program in Eswatini and the country is not eligible for Global Alliance for Vaccines and Immunization (GAVI) procurement of HPV vaccines, and yet the triad of HIV, sexually transmitted infections (STI) and cervical cancer generates a severe disease burden warranting immediate introduction of this intervention. Given the global limitations in vaccine supply and the high cost for procurement, country programs, including in Eswatini, must optimize vaccine resources in order to maximize HPV vaccine coverage.

Details
Condition HPV Infection, Hiv, HPV Vaccine
Treatment Gardasil ® 9
Clinical Study IdentifierNCT04982614
SponsorColumbia University
Last Modified on26 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

For people living with HIV receiving two-dose regimen
Females 9-26 years and males 9-14 years
Documented HIV infection
Aware of HIV+ status
Currently receiving antiretroviral treatment (ART) for HIV infection for at least six months
Living in Eswatini
For individuals 18+ years: able to provide informed consent
For individuals 15-17 years: able to provide informed assent
For individuals 9-14 years of age: able to provide informed assent AND accompanied by an adult caregiver who is able to give informed consent
Intending to remain in the vicinity of the study sites for the study period
For reference group of HIV-uninfected women receiving three-dose regimen
Females 15-26 years
Documented negative HIV test at baseline
Living in Eswatini
Able to provide informed assent (15-17 years) or informed consent (18-26 years)
Intending to remain in the vicinity of the study sites for the study period

Exclusion Criteria

For all participants
Diagnosis of other immunosuppressive diseases or receipt of immunosuppressive medications
Diagnosis of other acute or chronic illness
Receipt of other vaccinations within 2-3 weeks before or after study vaccination
Receipt of blood-derived products within 6 months before or during the study
Previous receipt of an HPV vaccine
Currently pregnant
Known allergies to a vaccine component
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note